Vyvanse is the first and only medication approved to treat moderate to severe Binge Eating Disorder (B.E.D.) in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.
Medicine isn’t right for all adults with moderate to severe B.E.D., so be sure to have an open and honest conversation with your doctor. Together, you can determine the course of action that's right for you and your specific needs.
Vyvanse could help you get control of your moderate to severe B.E.D.Talk to your doctor
Binge Eating Disorder, or B.E.D., is something I have…not something I do.
When my doctor told me I had moderate B.E.D., it explained why my eating was so out of control.
I’d often eat a lot more than normal in a short period of time, in secret. It was so upsetting. My doctor told me about Vyvanse, the first medicine approved for adults with moderate to severe B.E.D.
Announcer: Vyvanse shouldn’t be used for weight loss, or to treat obesity.
It has a high risk of abuse or dependence.
Selling or sharing Vyvanse may harm others and is illegal. Store it safely.
Do not take it if you take MAOIs or are allergic to stimulants.
Some patients taking stimulants like Vyvanse experienced: sudden death, stroke, heart attack and increased blood pressure and heart rate.
Call the doctor if you have chest pain, shortness of breath, or fainting.
New or worsening mental illness has occurred while taking stimulants. Call the doctor if you have changes in mood, behavior, or thoughts.
Circulation problems in the fingers and toes can occur.
Call your doctor if they feel numb, cool, painful, are sensitive to temperature, change color from pale, to blue, to red, or develop unexplained wounds.
A potentially life-threatening condition called Serotonin Syndrome may occur if Vyvanse is taken with certain other medicines.
Call your doctor or go to the emergency room if you experience: changes in mood or mental status, coma, problems with muscle control or tension, fast heartbeat, sweating, fever, nausea, vomiting, or diarrhea.
Jaime: Ask your doctor about Vyvanse for moderate to severe B.E.D.…so food can just be food again.
In two 12-week studies of adults who were diagnosed with moderate to severe B.E.D., Vyvanse was proven to reduce weekly binge days (a day with at least 1 binge episode).
At the end of both Study 1 and Study 2, adults with moderate to severe B.E.D. who took Vyvanse experienced, on average, significantly fewer binge days per week compared to those who took placebo. The change in binge days per week for adult patients with moderate to severe B.E.D. from the start of the study to the end was measured using a statistical measure called the LS-Mean.
*On average from the start of the 12-week study to its end.
Do not take Vyvanse if you are taking or have taken within the past 14 days an anti-depressant called a monoamine oxidase inhibitor (MAOI) or are sensitive to, allergic to, or had a reaction to other stimulant medications.
Concerned about side effects? Talk to your doctor. Learn more.
The same 2 studies also looked at obsessive binge eating thoughts and compulsive binge eating behaviors. A tool used by doctors called the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) measured Vyvanse compared to placebo.
†At the final visit of each of the 12-week studies.
In the 2 studies, doctors also rated patients as much improved or very much improved ("improved"), or not improved, using the Clinical Global Impressions-Improvement rating scale(CGI-I).
In the 2 studies, the percentage of patients who had no binge eating episodes in the last 4 weeks were measured. This was defined as a patient who experienced no binge eating episodes during the 4 weeks leading up to the patients’ last visit of the study. Patients taking Vyvanse were more likely to have no binge eating episodes during this 4-week time period compared to patients taking placebo.
In this study, patients who initially responded to Vyvanse had a longer time to relapse compared to those who were switched to placebo.
Relapse was defined as a worsening in both the number of binge eating days (2 or more per week for 2 consecutive weeks) and the symptom severity score determined by the healthcare provider.
Adverse events seen in this study were consistent with those seen in other studies of adult patients with moderate to severe B.E.D. on Vyvanse.